NEW YORK (GenomeWeb News) – OptiGene today announced an agreement to license Eiken Chemical's LAMP gene amplification technology.
Separately, Eiken this week said that it also is licensing the technology to the UK Veterinary Laboratories Agency.
As part of its agreement, OptiGene will develop, manufacture, and sell nucleic acid amplification reagents for research use.
OptiGene, based in West Sussex, UK, develops instruments and reagents for the amplification and detection of DNA and RNA, and said that its Genie II instrument offers "ultra-rapid" amplification with highly sensitive fluorescence detection on one platform. Used with the firm's reagents, target detection can be achieved in 10 minutes or less.
"Consequently, this is a genuine alternative to PCR," OptiGene said.
Eiken, based in Tokyo, also announced a deal licensing the LAMP technology to VLA, an executive agency of the Department for Environment, Food, and Rural Affairs. VLA provides research, surveillance, and laboratory services for animal and public health.
As part of its agreement with Eiken, VLA will develop, manufacture, and provide testing for nucleic acid diagnostics for veterinary purposes and environmental monitoring, Eiken said.
Financial and other terms of the two deals were not disclosed.
"Eiken aims to continue to apply the LAMP method to such fields as medicine, agriculture, food, animal husbandry, environmental protection, and also contribute to the expansion of the genetic testing market," it said.
LAMP stands for Loop-mediated Isothermal Amplification. It uses four different primers to recognize six distinct regions on a target gene for detection and amplification in a single step, the company said on its website.